Fondaparinux Market

1. Fondaparinux Market Size, Share and Industry Growth Forecast, 2027 Clinical Nutrition Market by Route of Administration (Oral, Enteral, and Parental), Application (Cancer, Metabolic Disorders, Gastrointestinal Disorders, Neurological Disorders and Others), and End User (Pediatric, Adult, and Geriatric): Global Opportunity Analysis and Industry Forecast, 2021-2028

2. Why Allied Market Research? FREQUENTLY ASKED QUESTIONS? Which are the leading market players active in the Fondaparinux market? What would be the detailed impact of COVID-19 on the market? What current trends would influence the market in the next few years? What are the driving factors, restraints, and opportunities in the Fondaparinux market? What are the projections for the future that would help in taking further strategic steps? INFALLIBLE METHODOLOGY To ensure high-level data integrity, accurate analysis, and impeccable forecasts ANALYST SUPPORT For complete satisfaction CUSTOMIZATION On-demand customization of scope of the report to exactly meet your needs TARGETED MARKET VIEW Targeted market view to provide pertinent information and save time of readers

3. Overview Fondaparinux (Arixtra) is a synthetic anticoagulant based on the pentasaccharide sequence that makes up minimal antithrombin (AT) binding region of heparin. Similar to low molecular weight heparins, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all. Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be advantageous in certain settings. Indications for fondaparinux includedeep vein thrombosis and pulmonary embolism and superficial vein thrombosis.It is the same sequence as UFH and LMWH for the binding to antithrombin, however it has no extra chain and thus, is not considered a heparin product. It is also known to not cause HIT, as seen with UFH and LMWH.

4. COVID-19 Scenario Analysis: Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing  to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

5. Surge In Number Of Mergers And Acquisitions To Propel The Market Increase in number of mergers and acquisitions is anticipated to help the industrygrow in the coming years. For instance, in September 2020, Mylan's planned a megamerger with Pfizer's Upjohn generics unit. Mylan will shell out $756 million for European rights to a suite of Aspen Pharmacare's sterile injectable anticoagulants that ranked in nearly a quarter-billion dollars.The Aspen acquisition will position Mylan as one of the largest producers of thrombosis products in Europe. This would help the market to gain traction during the forecast period.

6. Key Market Players • Some of the key players operating in the global clinical nutrition market include: • Bayer Healthcare AG, • GlaxoSmithKline plc., • Boehringer Ingelheim, • Sanofi S.A., • Apotex, • Abbott India Limited, • Aspen Holdings, • Pfizer Inc., • Bristol-Myers Squibb Company, • Eisai Inc., • WisMed Pharmaceuticals • Kaifeng Pharmaceutical.

7. This study presents the analytical depiction of the global Fondaparinux industry along with the current trends and future estimations to determine the imminent investment pockets. The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Fondaparinux market share. The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Fondaparinux market growth scenario. Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. The report provides a detailed global Fondaparinux market analysis based on competitive intensity and how the competition will take shape in coming years. Key Findings Of The Fondaparinux Industry Find out more at the Allied Market Report store https://www.alliedmarketresearch.com/fondaparinux-market-A10494

8. ABOUT ALLIED MARKET RESEARCH Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: +1-800-792-5285 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com